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ABSTRACT Escherichia coli multidrug resistance protein E (EmrE) is an integral membrane protein spanning the inner
membrane of Escherichia coli that is responsible for this organism’s resistance to a variety of lipophilic cations such as
quaternary ammonium compounds (QACs) and interchelating dyes. EmrE is a 12-kDa protein of four transmembrane helices
considered to be functional as a multimer. It is an efﬂux transporter that can bind and transport cytoplasmic QACs into the
periplasm using the energy of the proton gradient across the inner membrane. Isothermal titration calorimetry provides
information about the stoichiometry and thermodynamic properties of protein-ligand interactions, and can be used to monitor the
binding of QACs to EmrE in different membrane mimetic environments. In this study the ligand binding to EmrE solubilized in
dodecyl maltoside, sodium dodecyl sulfate and reconstituted into small unilamellar vesicles is examined by isothermal titration
calorimetry. The binding stoichiometry of EmrE to drug was found to be 1:1, demonstrating that oligomerization of EmrE is not
necessary for binding to drug. The binding of EmrE to drug was observed with the dissociation constant (KD) in the micromolar
range for each of the drugs in any of the membrane mimetic environments. Thermodynamic properties demonstrated this
interaction to be enthalpy-driven with similar enthalpies of 8–12 kcal/mol for each of the drugs in any of the membrane mimetics.
INTRODUCTION
Multidrug transporters recognize and extrude a wide range of
toxic compounds from the cell. These transporters have been
divided into four major families based on sequence and
substrate speciﬁcity: the major facilitator superfamily, ATP-
binding cassette family, resistance/nodulation/cell division
family, and the small multidrug resistance (SMR) family
(Paulsen et al., 1996; Putman et al., 2000). The SMR family
can be divided further into two categories: small multidrug
efﬂux proteins and Sug proteins (Edwards and Turner, 1998;
Paulsen et al., 1996). Members of the SMR family have
;110 residues and are the smallest known functional unit of
multidrug resistance. Studies have shown SMR transporters
to be composed of a four-helix antiparallel bundle (Arkin
et al., 1996; Edwards and Turner, 1998; Mordoch et al.,
1999; Paulsen et al., 1995; Schwaiger et al., 1998).
Ethidium multidrug resistance protein (EmrE) is an SMR
protein found in Escherichia coli, which extrudes lipophilic
cations such as quaternary ammonium compounds from the
cell resulting in bacterial resistance to these toxic compounds
(Paulsen et al., 1996; Schuldiner et al., 1997; Yerushalmi and
Schuldiner, 2000a,b). Using the energy of the proton gradient
across the inner membrane of E. coli, EmrE transports two
protons across the membrane into the cytoplasm while
transporting drug from the cytoplasm into the periplasm,
antiport to the proton translocation (Fig. 1) (Glaubitz et al.,
2000; Lebendiker and Schuldiner, 1996; Muth and
Schuldiner, 2000; Yerushalmi and Schuldiner, 2000a,b;
Yerushalmi et al., 2001). The oligomerization of EmrE
subunits has been suggested to be necessary for this transport
to provide multiple Glu14 residues for both drug and proton
binding (Koteiche et al., 2003; Ma and Chang, 2004).
Whether or not the drug partitioning into the membrane is
necessary to access the binding site of EmrE is still unknown.
The afﬁnities of various lipophilic cations to EmrE in
different membrane mimetics were examined using iso-
thermal titration calorimetry (ITC) to determine the energet-
ics and stoichiometry involved.
EXPERIMENTAL PROCEDURES
Puriﬁcation of EmrE
EmrE protein was expressed from E. coli strain LE392Dunc containing the
expression plasmid pMS119EH with the cloned emrE gene positioned
behind a tac-promoter. Cells were grown to a density of 0.5 (A600) in 1 L
Terriﬁc Broth inoculated at 37C and IPTG was added to a ﬁnal con-
centration of 0.1 mM. The cells were then incubated for 3 h, harvested by
centrifugation, and thoroughly washed with SMR A buffer (50 mM MOPS,
8% glycerol, 5 mM EDTA, 1 mM DTT, pH 7). Cells were resuspended in
SMRA buffer with 100mMPMSF and lysed by two passes through a French
press (16,000 psi). A low speed centrifugation (9000 3 g for 15 min)
removed the heavy cellular constituents and unlysed cells, followed by
a high-speed spin (110,000 3 g for 1.5 h) to collect the membrane fraction.
The membranes were resuspended in SMR A buffer and diluted to a ﬁnal
protein concentration of 10 mg/mL.
EmrE can be puriﬁed from membranes using organic solvent extraction
as described previously (Winstone et al., 2002). Ten milliliters of the
membrane fraction was extracted with 300 mL of 3:1 chloroform/methanol
(CM). Fifty milliliters of double-distilled water was added to separate the
water-soluble constituents from the organic phase. The organic phase was
collected and brieﬂy centrifuged to ensure complete phase separation of the
aqueous layer. The organic phase was then evaporated below 6 mL using
a rotovap. The protein was further puriﬁed and separated from any extracted
lipid using Sephadex LH-20 hydrophobic chromatography (Sephadex,
Amersham, Piscataway, NJ) with an isocratic elution in 1:1 CM solvent
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using an Akta¨ puriﬁer (Akta¨, Amersham). Solvent from the puriﬁed EmrE
was removed under N2 gas and the dried protein was stored at 70C until
use. Protein puriﬁed in this fashion is easily reconstituted into small
unilamellar vesicles (SUVs) and demonstrates transport activity (Winstone
et al., 2002).
Solubilization of EmrE in detergent
Sodium dodecyl sulfate (SDS) (from BioRad, Mississauga, Ontario,
Canada), and N-dodecyl-b-D-maltoside (DM) (Anatrace, Maumee, OH)
were found to solubilize this protein at useful levels. Stock detergent
solutions were made with 8% w/v SDS detergent in SMR B buffer (5 mM
MOPS, 10 mMNaCl, 10 mMdithiothreitol (DTT), pH 7) and 2% w/v DM in
SMR B buffer. Each tube of dried EmrE was exposed to 300 mL of the
desired detergent solution. The EmrE suspension was vortexed for 2 h at
room temperature followed by an overnight freeze-thaw cycle at 20C.
The sample was then centrifuged at 14,000 3 g for 10 min to remove any
insolubles. The pellet was discarded and the protein concentration of the
supernatant was determined by a modiﬁed Lowry assay (Peterson, 1977),
and diluted with its respective detergent solution in SMR B buffer so that the
EmrE concentration was 2 mg/ml. This sample was stored at 70C for
later use.
Reconstitution of EmrE into small
unilamellar vesicles
A tube of dried EmrE was resuspended in 110 mL of 3:1 CM. Of the 110 mL,
10 mL was set aside and dried under N2 gas. The dry pellet was resuspended
in SDS solution as previously described and a modiﬁed Lowry assay
(Peterson, 1977) was carried out on this sample to determine the protein
content in the remaining 100 mL of EmrE solution. Two milligrams of EmrE
was removed from this suspension, added to 1.5 mL of 25 mg/ml E. coli
polar lipid extract (from Avanti, Alabaster, AL), and dried under N2 gas.
One milliliter of SMR C buffer (0.5 mM MOPS, pH 7) was added to the
dried pellet. The sample was vortexed for 20 min at room temperature to
resuspend the pellet. Five freeze-thaw cycles were carried out on this sample
at 70C. Three cycles of sonication were carried out on the sample for 3 s
each at 25% power (5 mA amplitude), and stored at 70C for later use.
SUVs were also constructed similarly in the absence of EmrE.
ITC calorimetry of EmrE
Prepared samples of EmrE in detergent or SUV solutions were thawed. To
exchange into a buffer lacking salt and reducing agent, 0.5 mL of EmrE
sample and 1.5 mL of SMR C buffer (0.5 mM MOPS, pH 7) with detergent
or SUVs was loaded on a 5-mL Hi Trap Desalting Column (Phamacia,
Amersham). The column had previously been equilibrated with six column
volumes of SMR C buffer before loading of EmrE. The column was eluted
with SMR C buffer, and the ﬁrst 2 mL of elution containing the EmrE
protein was collected. The eluted EmrE was diluted to a ﬁnal concentration
of 0.480 mg/ml (40 mM), and degassed in a thermovac at room temperature
for 5 min. The degassed sample was injected into the sample cell of a
MicroCal ITC calorimeter (MicroCal, Origin, Northampton, MA). Calo-
rimetry trials were carried out at 25C.
Ligand consisting of ethidium (Et), proﬂavin (Pro), cetylpyridinium
(CTPC), methyl viologen (MV), or tetraphenylphosphonium (TPP) sol-
ubilized in SMR B buffer containing the same concentration and type of
lipid (SDS, DM, or SUV) used in the protein sample was prepared as the
titrant. Sixty injections of this titrant containing either 0.5 mM ligand for
strong interactions or 2.0 mM ligand for weaker interactions were injected
into the ITC sample cell.
Injections occurred at intervals of 240 s, and the duration time of each
injection was 8 s. Heat transfer (mcal/s) was measured as a function of
elapsed time (seconds). Heats of dilution were subtracted from the heats
collected in the corresponding experiments. Independent preparations of
EmrE were used in this experiment to verify that binding trends were
consistent.
Calorimetry trials were also carried out in the absence of EmrE in the
same experimental conditions as described above. No change in heat re-
leased was observed in the injections throughout the experiment.
ITC of drug binding to membrane mimetics
Each mimetic and drug was tested for binding. The titrant was made up of
40 mM drug in SMR B buffer (lacking detergent or SUVs), whereas the sam-
ple cell contained either 4 mM detergent in SMR B buffer, or SUVs in
SMR B buffer. The SUVs were prepared as described previously, with the ex-
ception of 0.70 ml of 25 mg/ml E. coli polar lipid extract being used
instead. Preparation of samples and calorimetry was carried out as previ-
ously described.
Thermodynamic calculations
From analysis of each generated thermogram, the heat of dilution (hdil) was
used to determine the heat of reaction (dhi) for each injection by the equation
ðdhiÞ ¼ ðhiÞ  ðhdilÞ; (1)
FIGURE 1 EmrE uses energy from
the proton gradient across the inner
membrane of Escherichia coli to efﬂux
quaternary ammonium compounds
from the cytoplasm to periplasm as
shown. Extramembrane (EM) loops and
N- and C-termini are labeled for clarity.
The topology was established by Son
et al. (2003).
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where hi is the heat released at a given injection calculated by the integration
of the respective injection peak. The integration of an injection peak was





where ntp is the total moles of protein in the cell. Plotting DH against the
molecular ligand/protein ratio produces a binding isotherm.
Nonlinear regression ﬁtting to the binding isotherm (ORIGIN software,
MicroCal) gave the equilibrium dissociation constant of the ligand KD. From
the value of KD, the free energy of binding (DG) and entropy of binding
(DS) can be calculated from the following relationships,
DG ¼ RT lnð1=KDÞ ¼ DH  TDS; (3)
where T is 273 K and R is 1.9872 cal/K per mol.
RESULTS
Isothermal calorimetry was employed to study the binding of
lipophilic cations to EmrE. In the experiments, the ligand
was in large excess over the protein which allowed the
binding reaction to be driven near completion. However,
before heats of binding could be detected at a sufﬁcient
signal/noise ratio, extensive exploration of experimental con-
ditions was carried out.
For an acceptable signal/noise ratio and consistent
baseline to be generated for analysis, many parameters of
the procedure had to be tested and several optimization trials
needed to be carried out. Preliminary trials (data not shown)
consistently had too low a signal to be analyzed. A range of
protein concentration from 0.05 to 0.5 mg/ml had been
tested. Until the protein concentration was increased to
a suitable level, little or no signal was detected. The ratio of
the molecules of EmrE to the molecules of ligand introduced
per injection had also been tested in the range of 0.1:10. It
was found that a ratio in the range of 10:4 was suitable for
measuring the heats evolved from EmrE binding to any of
the substrates in any of the membrane mimetics. A modiﬁed
solubilization protocol to achieve this concentration was
employed as described above, after various parameters and
methods of resolubilizing the dried protein had been tested.
Such parameters included intensities, time intervals, and
cycles of sonication; time and temperature of vortexing dur-
ing resuspension; and concentrations of detergent or E. coli
polar lipid extract present during resuspension. Much ex-
perimentation with these parameters had to be carried out
before a suitable signal/noise ratiowas achieved. The protocol
described in the methods above consistently yields an EmrE
concentration .2 mg/ml (166 mM) in each of the mimetic
environments, which is necessary for a sufﬁcient signal/noise
ratio. It was also discovered that concentrations of NaCl and
reducing agent DTT could be successfully removed or
decreased in the EmrE samples using a size exclusion column
for buffer exchange without affecting solubilization or
functionality of the protein in the short term of the experiment.
Both components add noise to the signal, especially DTT,
which undergoes oxidation throughout the experiment. It was
not until parameters of protein, NaCl, and DTT concentration
were optimized that a sufﬁcient signal was achieved.
The heats of binding are measured in a thermogram
Fig. 2 A which demonstrates a titration of 30 injections con-
taining 2 mM of ethidium into a solution of 40 mM EmrE
reconstituted into SUVs. Each peak represents an injection
of drug. Negative deﬂections from the baseline upon addi-
tion of drug indicate that heat was evolved during binding
(an exothermic ligand binding event).
Binding isotherms derived from multiple thermograms of
ethidium-EmrE binding in SUVs are displayed in Fig. 2 B
with a curve of best ﬁt through the compiled data points. The
stoichiometry and values of KD extracted from these curves
are summarized in Table 1. Independent preparations of
EmrE make up this data and demonstrate the reproducibility
of the experiment.
The values of KD were in the micromolar range which is
similar to the dissociation constants reported for other
FIGURE 2 Representative titration calorimetry of EmrE in SUVs with
ethidium. (A) Each peak corresponds to the injection of 8 ml of 0.5 mM
ethidium in SUVs into the reaction cell containing 40 mM EmrE in SUVs.
The concentration of E. coli polar lipid that formed SUVs in this experiment
was 37.5 mg/ml. (B) Cumulative heat of reaction is displayed as a function
of the injection number. The solid line is the least-squares ﬁt to the
experimental data of separate trials (indicated by symbols 3, n, and h). It
corresponds with a KD of 5.5 mM. (C) Linearization of the data in a single
trial in a Scatchard plot as an alternative way of measuring the KD.
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multidrug-resistant proteins to these drugs (Lewinson and
Bibi, 2001; Marham et al., 1996; Va´zquez-Laslop et al.,
1999). In comparing afﬁnities of the various drugs to EmrE
reconstituted in SUVs and in DM environments, the
ethidium and proﬂavin ligands gave rise to stronger binding
than tetraphenylphosphonium and methyl viologen in which
binding was weaker and even undetected for tetraphenyl-
phosphonium in the SUV mimetic (Table 1). The shift from
a more sigmoidal plot of the binding isotherm in the case of
ethidium (Fig. 2 B) toward a more hyperbolic plot in the case
of methyl viologen (Fig. 3 B) demonstrates stronger versus
weaker binding, respectively. In the SDS mimetic, each of
the ligands bound with similar afﬁnities (Table 1). In the case
of using cetylpyridinium (CTPC) ligand, binding was not
detected in any given membrane mimetic.
In regard to the thermodynamic data, there did not appear
to be any trends in the enthalpy or entropy of the reaction
among the drugs in any given environment (Table 1). The
inﬂection point of the isothermograms occurred at ;1:1
(mol/mol) of drug to protein, indicating a stoichiometry of
one molecule of drug bound to one molecule of protein.
Control experiments were performed in which each ligand
in each of the membrane mimetics was injected into the ITC
sample cell containing the same membrane mimetic in the
absence of EmrE. These trials were carried out using the
same concentrations and injection volumes as carried out
previously in the presence of protein. Heat released during
these trials was constant for each injection and could only be
observed when higher volumes of injectant were used. It was
measured that each injection contributed ,0.9 mcal of heat
for each ligand and membrane mimetic, well below the heat
released upon drug-EmrE binding. These experiments
demonstrated that the exothermic heats of drug partitioning
from its membrane mimetic in the syringe into a greater
amount of the membrane mimetic in the sample cell were
negligible in contrast to drug-protein binding and could be
disregarded.
To explore drug-lipid partitioning interactions, drug in the
absence of each membrane mimetic was titrated into each of
the membrane mimetic solutions. A sample thermogram of
EtBr partitioning into DM is illustrated in Fig. 4. The
interaction was too weak to determine the stoichiometry of
drug binding to membrane mimetic and the conﬁdence in the
values is less because of the weaker binding, but the relative
magnitude between experiments is still meaningful. It was
TABLE 1 Dissociation constants and thermodynamic data for binding of drug to EmrE in various mimetic environments at 25C
Environment Drug KD (mM) DG (kcal/mol) DH (kcal/mol) DS (kcal/mol per K)
SUV Ethidium 5.5 6 2.1 7.2 6 0.2 10.7 6 0.1 11.8 6 1.0
Methyl viologen 38.2 6 8.7 6.1 6 0.1 7.5 6 0.7 4.9 6 2.7
Proﬂavin 10.7 6 2.8 6.8 6 0.2 8.9 6 0.2 7.1 6 1.0
TPP Could not be determined
SDS Ethidium 5.2 6 1.4 7.2 6 0.2 11.4 6 0.1 14.0 6 0.6
Methyl viologen 5.4 6 1.2 7.2 6 0.1 9.7 6 0.2 8.4 6 0.6
Proﬂavin 4.5 6 0.8 7.3 6 0.1 10.6 6 0.2 11.1 6 0.9
TPP 4.8 6 0.8 7.3 6 0.1 12.1 6 0.1 16.0 6 0.5
DM Ethidium 6.3 6 1.0 7.1 6 0.1 10.9 6 0.1 12.7 6 0.2
Methyl viologen 46.2 6 10.5 5.9 6 0.1 7.7 6 1.6 7.1 6 4.7
Proﬂavin 5.2 6 0.9 7.2 6 0.1 9.6 6 0.1 7.8 6 0.5
TPP 25.5 6 6.2 6.3 6 0.1 9.9 6 0.5 12.2 6 2.2
Each value represents three separate trials.
FIGURE 3 Representative titration calorimetry of EmrE in SUVs with
methyl viologen. (A) Each peak corresponds to the injection of 8 ml of 0.500
mMmethyl viologen in SUVs into the reaction cell containing 40 mMEmrE
in SUVs. The concentration of E. coli polar lipid that formed SUVs in this
experiment was 37.5 mg/ml. (B) Cumulative heat of reaction is displayed as
a function of the injection number. The solid line is the least-squares ﬁt to the
experimental data of separate trials (indicated by symbols 3, n, and h). It
corresponds with a KD of 38.2 mM. (C) Linearization of the data in a single
trial in a Scatchard plot as an alternative way of measuring the KD.
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observed that lipid partitioning of each drug into any of the
membrane mimetics displayed similar weak binding (Table
2). The exception was CTPC, which bound to SUVs and SDS
with dissociation constants in the high nanomolar range,
whereas binding was undetected in DM. There were signi-
ﬁcant enthalpic and entropic contributions in the case of
CTPC binding to membrane mimetic. In binding CTPC to
SUVs,DGwas observed to be8.3 kcal/mol withDH andDS
at5.3 kcal/mol and 10.1 cal/mol K, respectively. In binding
CTPC to SDS,DGwas observed to be9.1 kcal/mol withDH
and DS at 6.4 kcal/mol and 8.9 cal/mol K, respectively.
The concentration of detergents used were well above the
critical micelle concentrations for SDS and DM. Aggregation
numbers of 62–101 for SDS (Anatracemeasurement) and 78–
149 for DM (VanAken et al., 1986, Anatrace measurement)
were used to determine the ratio of micelles/EmrE subunits.
This ratio is on an order of 40 in SDS, and 4 in DM.
DISCUSSION
Studies of multidrug-resistant proteins have demonstrated
two types of residues involved in binding to quaternary
ammonium compounds. Structures of the compounds are
shown in Fig. 5. The ﬁrst essential residue is a negatively-
charged acidic residue for binding to the positive charge of
the ligand (Edgar and Bibi, 1999; Ekaterina et al., 2001;
Muth and Schuldiner, 2000; Paulsen et al., 1996). This
residue is highly conserved among multidrug resistant
proteins (Paulsen et al., 1996). The Glu14 residue of EmrE
serves such a purpose (Muth and Schuldiner, 2000). The
second type of residue involved in ligand binding are
aromatic residues (Dougherty, 1996; Zhong et al., 1998).
Crystallographic studies of proteins involved in multidrug
resistance have shown aromatic residues involved in van der
Waal and p-p interactions with the aromatic rings of the
ligand, as well as p-interactions with the positive charge on
the ligand (Ekaterina et al., 2001; Schumacher and Brennan,
2003). EmrE contains several aromatic residues which may
assist in this interaction. Several aromatic residues are highly
conserved among SMR proteins (Putman et al., 2000), and
one or more of these residues may aid in binding to the drug.
FIGURE 4 (A) Thermogram of EtBr binding to SUVs with a KD of 0.58
mmol. Each peak corresponds to the injection of 8 ml of 40 mM EtBr
solution into the reaction cell containing SUVs. The concentration of E. coli
polar lipid that formed SUVs in this experiment was 17.5 mg/ml. (B)
Cumulative heat of reaction is displayed as a function of the injection
number. The solid line is the least-squares ﬁt to the experimental data points.
It corresponds with aKD of 0.58 mM. (C) Linearization of the data in a single
trial in a Scatchard plot as an alternative way of measuring the KD.
TABLE 2 Binding constants for binding of drug to various mimetic environments at 25C
Environment Drug KD (mM) DG (kcal/mol) DH (kcal/mol) DS (cal/mol per K)
SUV Ethidium 0.6 4.4 2.1 7.8
Methyl viologen 4.1 3.3 2.3 3.1
Proﬂavin 2.1 3.7 2.0 5.6
TPP 0.2 4.9 2.7 7.6
CTPC 8.4 3 104 8.3 5.3 10.1
SDS Ethidium 0.3 4.9 2.6 7.7
Methyl viologen 1.8 3.8 2.6 3.8
Proﬂavin 0.4 4.7 2.4 7.9
TPP 0.4 4.6 2.0 8.7
CTPC 2.4 3 104 9.1 7.4 5.6
DM Ethidium 5.2 3.1 1.5 5.4
Methyl viologen 11.8 2.6 1.0 5.4
Proﬂavin 17.1 2.4 1.6 2.8
TPP 10.8 2.7 1.3 4.8
CTPC Could not be determined
The values in this table represents data from a single trial of three runs.
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Mutation of Y40, Y53, F44, Y60, or W63 to a cysteine
residue results in a non-expressed or less-functional protein
(Mordoch et al., 1999; Yerushalmi and Schuldiner, 2000a,b).
This suggests that one or more of these residues may be in-
volved in assembly or protein-ligand interactions.
Ligand interactions with the membrane have also been
considered. It has been observed with other similar qua-
ternary ammonium compounds such as anthracyclines,
which interact with multidrug resistant protein P-glycopro-
tein partition into the headgroup/acyl chain interface of the
inner leaﬂet of the membrane (Gallois et al., 1998). It was
also observed that different headgroups (charged/zwitter-
ionic/neutral) and differently charged drugs (monovalent/
divalent) did not signiﬁcantly contribute to partitioning of
drug into the lipid (Gallois et al., 1998), which reﬂects the
data collected in Table 2. Rather it is the hydrophobicity of
the drug that is the major contributor of membrane
partitioning (Gallois et al., 1998). This would make the
binding interaction entropically favorable as well, since the
water forming a clathrate cage around the hydrophobic
regions of the drug are released upon the drug’s partitioning
into the lipid (Butler et al., 2004). Our goal was to examine
whether or not drug partitioning into the membrane mimetic
occurs to account for the possibility that EmrE recruits drug
from the membrane. Drug binding to membrane mimetic was
evaluated to asses this issue. Each drug demonstrated the
ability to partition into various membrane mimetics (Table
2). It should be noted that drug-membrane mimetic interac-
tions (Table 2) are still considerably weaker than drug bind-
ing to EmrE (Table 1), which is still the more energetically
favorable reaction.
Under investigation is whether EmrE binds drug from the
inner leaﬂet of the membrane or if drug is accessible to EmrE
via the cytoplasm. Multidrug resistant proteins Lmr, MexA-
MexB-OmpR, QacA, and P-glycoprotein have demonstrated
interaction with drug solubilized in the inner leaﬂet of the
membrane (Bolhuis, 1996; Bolhuis et al., 1996; Edgar and
Bibi, 1999; Homolya, 1993; Mitchell et al., 1998; Ocaktan
et al., 1997; Shapiro and Ling, 1997). A mechanism of
multidrug resistance is the ﬂipase activity of MDR proteins
to relocate drugs from the inner leaﬂet to the outer leaﬂet of
the membrane. This study has provided evidence of each
drug having the capability to partition into different
membrane mimetics (Fig. 2), so it is possible that EmrE
may bind to drug solubilized in the membrane much like
what is proposed for other multidrug resistant proteins.
Crystallographic studies have suggested accessibility of drug
to EmrE from both the membrane and cytoplasm (Ubarret-
xena-Belandia et al., 2003). However, it is still uncertain in
what direction the drug enters the binding site of EmrE.
In comparing the chemical structures of the various
ligands in this experiment to the calorimetric results ob-
tained, certain postulations may be made. Firstly, the SUV
and DM environments do not seem to alter the binding of
EmrE to ligand in any way with the exception of TPP. TPP
binding to EmrE was not observable by the method of ITC in
the SUV mimetic but could be detected in the DM mimetic.
It was shown that TPP still bound to each of these membrane
mimetics (Table 2). Ethidium (Et) and proﬂavin (Pro)
ligands showed stronger binding than the tetraphenylphos-
phonium (TPP) and methyl viologen (MV) ligands. Steric
hindrance from the phenyl rings on the TPP substrate may
make it less accessible to the binding site of EmrE. Likewise,
the second positive charge on MV may interfere with its
accessibility to the EmrE binding site.
SDS is an environment that denatures many soluble
proteins; however, many membrane proteins retain their
structure and have been studied in this mimetic (van de Ven
et al., 1993; Mortishire-Smith et al., 1995; Lee et al., 2003;
Sulistijo et al., 2003). Circular dichroism and ﬂuorescence
studies performed in SDS, DM, and SUVs have shown that
EmrE in each of these environments has a similar structure
(Federkeil et al., 2003). EmrE is in a slightly more open
conformation in SDS than DM and SUVs (Federkeil et al.,
2003), which could make its binding site more accessible to
drug. The TPP and MV show binding with an afﬁnity similar
to that of Et and Pro ligands in this environment, perhaps as
a result of better accessibility to the binding site for these
ligands. It should also be noted that since the structure of
EmrE in the different mimetics is similar as assessed by CD
and ﬂuorescence, each of the mimetics without protein bind
drug similarly with dissociation constants in the millimolar
range (Table 2), and the binding of EmrE to drug is also
similar in each of these different mimetics (Table 1).
The ITC method was able to detect CTPC binding to the
membrane mimetics but not to EmrE. The presence of the
FIGURE 5 Structures of lipophilic cations used in this study.
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acyl chain of this molecule would interact with the lipid more
favorably. Partitioning out of the lipid and into the binding
site of EmrE may be energetically unfavorable for this drug.
EmrE is a protein known to form homo-oligomers (Ma
and Chang, 2004; Muth and Schuldiner, 2000; Tate et al.,
2001; Torres and Arkin, 2000; Rotem et al., 2001;
Ubarretxena-Belandia et al., 2003; Yerushalmi et al.,
1996). The most recent x-ray crystallographic study has
reported a tetrameric EmrE (Ma and Chang, 2004). The
results here suggest that oligomerization is not necessary for
EmrE binding to drug. The binding stoichiometry of the
EmrE binding drug in our study was observed to be 1:1. In
the environments of SDS and DM, EmrE has been shown to
exist as a monomer when puriﬁed using the organic solvent
extraction methodology (Winstone et al., 2005). Both
environments display a binding stoichiometry of 1:1 to
each of the drugs, indicating that the monomer by itself is
capable of binding drug. The stoichiometry of drug-EmrE
binding in SUVs which better approximates the membrane
of E. coli was also found to be 1:1. Considering that the
micelle/EmrE ratio is 40 in SDS and 4 in DM and that one
EmrE subunit occupies one DM micelle (Winstone et al.,
2005), it can be concluded that the EmrE monomer can bind
substrate. However, it is still possible that oligomerization is
necessary for transport of the drug across the membrane as
the other EmrE subunits are required to bind protons
necessary for the antiport of drug with protons (Muth and
Schuldiner, 2000; Yerushalmi and Schuldiner, 2000a,b).
Additionally, dimerization could further stabilize the binding
providing a second-half of a binding site, and this has been
observed in studies in which a multimer of EmrE was present
in which TPP dissociation constants in the nanomolar range
have been reported (Rotem et al., 2001; Tate et al., 2003).
Whether oligomerization occurs before or after drug binding
to EmrE has yet to be determined, although these experi-
ments demonstrate that oligomerization is not necessary for
binding to drug substrate.
Crosslinking and crystallographic studies have shown that
oligomeric EmrE has two Glu14 residues in close proximity
with one another (Koteiche et al., 2003; Ma and Chang,
2004; Ubarretxena-Belandia et al., 2003). Although the
EmrE monomer is capable of binding drug as shown in this
and other studies (K. A. Duncalf and R. J. Turner,
unpublished), it has been postulated that the formation of
a dimer better stabilizes its interaction (Butler et al., 2004)
with drug, since Glu14 residues from both subunits serve to
stabilize the positive charge on the drug (as opposed to just
one in the monomeric form). This interaction must still be
weak enough to accommodate drug release during transport.
Studying EmrE puriﬁed in different ways and solubilized in
different membrane mimetics has resulted in different
oligomeric states (Elbaz et al., 2004; Ma and Chang, 2004;
Tate et al., 2003; Ubarretxena-Belandia et al., 2003;
Winstone et al., 2005). This could account for higher
binding afﬁnities for TPP observed in other publications in
the nanomolar range in which a dimer or higher order of
oligomerization may be present (Elbaz et al., 2004; Muth and
Schuldiner, 2000; Tate et al., 2003).
In conclusion, this study of isothermal titration calorim-
etry has demonstrated the weak, nonspeciﬁc binding of
EmrE to a variety of lipophilic cationic drugs. It has dem-
onstrated that this interaction is similar in various mem-
brane mimetics. Also the binding stoichiometry of drug to
EmrE has been shown to be 1:1. Although the oligomer
can accommodate the protons required for transport as
discussed, oligomerization is not required for the binding
event as demonstrated by this study. Using ITC, the olig-
omerization state and thermodynamics of EmrE binding to li-
pophilic cationic drugs in different membrane mimetics is
now understood.
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